智通财经APP获悉，香港联交所最新数据显示，11月24日，摩根大通增持微创医疗(00853)8906.0433万 股，每股作价10.4413港元，总金额约为9.3亿港元。增持后最新持股数目约为2.76亿股，持股比例为 14.44%。 ...

Group 1 - The CRO concept stocks are experiencing a collective rebound, with the CSI Hong Kong Stock Connect Medical Theme Index rising by 2.73% as of November 24, 2025 [1] - Notable individual stock performances include Tigermed (03347) increasing over 9%, and other companies like Hansoh Pharmaceutical (03692), MicroPort Medical (00853), and WuXi AppTec (02359) also seeing gains [1][2] - The Hong Kong Medical ETF (159366) has risen over 2%, and over the past six months, it has accumulated a 29.35% increase [1][2] Group 2 - The innovative drug industry is benefiting from dual advantages of policy support and explosive demand, which are activating new drug research and development needs, positively impacting the CXO sector [3] - Among 29 listed companies in the A-share CXO sector, 20 reported year-on-year revenue growth in the first three quarters, indicating strong industry resilience [3] - WuXi AppTec's unique "integrated, end-to-end" CRDMO business model has driven steady growth, with total revenue of 32.86 billion yuan in the first three quarters of 2025, a year-on-year increase of 18.6%, and net profit attributable to shareholders rising by 84.8% to 12.08 billion yuan [3] Group 3 - The high growth of the CXO sector is supported by the trend of pharmaceutical companies outsourcing R&D and production to specialized CXO firms, which helps reduce costs and improve efficiency [4] - CXO companies are enhancing their service capabilities through continuous technological development and scale expansion, leading to deeper integration with pharmaceutical companies [4] - As of October 31, 2025, the top ten weighted stocks in the CSI Hong Kong Stock Connect Medical Theme Index accounted for 62.83% of the index, indicating a high concentration in the market [4]

Group 1 - The core point of the article is that southbound funds have increased their holdings in MicroPort Medical (00853.HK) by 211,600 shares on November 20, 2025, with a total net increase of 3.815 million shares over the last five trading days and 16.5963 million shares over the last 20 trading days [1][2] - As of now, southbound funds hold 896 million shares of MicroPort Medical, accounting for 46.84% of the company's total issued ordinary shares [1][2] Group 2 - The trading data shows fluctuations in shareholding, with a total holding of 896 million shares on November 20, 2025, reflecting a change of 0.02% [2] - The company operates in the medical device sector, focusing on sales, production, research, and development across eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, and surgical robotics [2]

| 麦植座长 | 次股東/董庫/嚴重信貸入債各 作出該購的賣人 / 費出或涉及时 每月的平均價 | | | 耗有權益的股份數量 佔已發行的商職單作的目 相關活黨股 賣權值得益 | | --- | --- | --- | --- | --- | | | 200 1955 100 - | | | (得参閲上述*註 南投票個發期(日/月/ 份權益 | | | | | | 团周分比 年) | | CS20251114E00460 UPMorgan Chase & Co. | 1101(L) | 17.319.839(L) | HKD 11,1430 | 193,530,128(L) 10.11(L)(11/11/2025 | | | 14015(S) | 4.172,432(S) | | 153,930,160(S) 8.04(S) | | | | | | 6,883,358(P) 0.35(P) | 格隆汇11月18日丨根据联交所最新权益披露资料显示，2025年11月11日，微创医疗(00853.HK)获 JPMorgan Chase & Co.以每股均价11.143港元增持好仓1731.98万股，涉资约1.93亿 ...

Core Insights - Southbound funds increased their holdings in MicroPort Medical (00853.HK) by 270,000 shares on November 13, 2025, while experiencing a net reduction of 2,834,000 shares over the past five trading days [1] - Over the last 20 trading days, southbound funds have increased their holdings on 13 occasions, resulting in a net increase of 21,939,700 shares [1] - As of now, southbound funds hold 892 million shares of MicroPort Medical, accounting for 46.64% of the company's total issued ordinary shares [1] Trading Data Summary - On November 13, 2025, total shares held were 892 million, with a change of 270,000 shares, reflecting a 0.03% increase [2] - On November 12, 2025, total shares held remained at 892 million, with a decrease of 1,038,100 shares, indicating a -0.12% change [2] - On November 11, 2025, total shares held were 276,680, with a reduction of 692,300 shares, showing a -0.08% change [2] - On November 10, 2025, total shares held were 894 million, with an increase of 171,400 shares, reflecting a 0.02% change [2] - On November 7, 2025, total shares held were 894,700, with a decrease of 1,545,000 shares, indicating a -0.17% change [2] Company Overview - MicroPort Medical is primarily engaged in the sales, production, research, and development of medical devices [2] - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [2]

Core Viewpoint - Bank of America Securities reaffirms "Buy" rating for MicroPort Medical (00853) due to attractive risk-reward profile and diversified high-value consumables product portfolio [1] Group 1: Business Growth Potential - The surgical robotics segment is expected to be a key growth driver, contributing 19% of total revenue by 2034 [1] - The company is addressing liquidity concerns and aims to achieve profitability by the first half of 2026 through cost control and divesting non-core assets [1] Group 2: Financial Projections - Total revenue forecasts for 2026 to 2034 have been raised by 0.1% to 1.5% [1] - Target price has been increased from HKD 16.8 to HKD 17 [1] Group 3: Shareholder Support - Shareholder Shanghai Industrial Group is expected to provide financial and operational support and will focus on improving the company's governance structure [1]

美银证券发布研报称，重申对微创医疗(00853)的"买入"评级，因其风险回报具吸引力，公司拥有多元 化的高价值耗材产品组合，其中手术机器人业务将成为未来关键增长动力，该行预期手术机器人于2034 年将贡献19%总收入。另外，该行认为微创医疗股东上实集团可能会提供财务及业务支持，并会着手于 公司的治理架构。公司亦正在化解流动性忧虑，而且透过成本控管及处置非核心资产，有望自2026年上 半年起实现盈利。该行将2026至2034年总收入预测上调0.1%至1.5%，目标价由16.8港元上调至17港元。 ...

Core Viewpoint - Bank of America maintains a "Buy" rating on MicroPort Medical, citing attractive risk-reward dynamics and a diversified high-value consumables product portfolio [1] Group 1: Business Growth Potential - The surgical robotics segment is expected to be a key growth driver, projected to contribute 19% of total revenue by 2034 [1] - The company is addressing liquidity concerns and aims to achieve profitability by the first half of 2026 through cost control and divesting non-core assets [1] Group 2: Financial Support and Governance - Shareholder Shanghai Industrial Group is anticipated to provide financial and operational support, as well as improvements in the company's governance structure [1] Group 3: Revenue Forecast and Target Price - Total revenue forecasts for 2026 to 2034 have been adjusted upward by 0.1% to 1.5%, with the target price slightly increased from HKD 16.8 to HKD 17 [1]

Core Viewpoint - MicroPort Medical (00853) has seen a stock increase of over 4%, currently trading at HKD 11.57 with a transaction volume of HKD 103 million, supported by a positive report from Bank of America Securities which maintains a "Buy" rating due to attractive risk-reward dynamics [1] Group 1: Financial Performance and Projections - Bank of America Securities expects that the surgical robotics segment will be a key growth driver for MicroPort Medical, projecting it to contribute 19% of total revenue by 2034 [1] - The company is addressing liquidity concerns and aims to achieve profitability by the first half of 2026 through cost control and divesting non-core assets [1] Group 2: Strategic Support and Governance - The report indicates that MicroPort Medical's shareholder, Shanghai United Imaging Healthcare Group, may provide financial and operational support, and is expected to focus on improving the company's governance structure [1]

Core Viewpoint - MicroPort Medical (00853) has seen a stock increase of over 4%, currently trading at HKD 11.57 with a transaction volume of HKD 103 million, indicating positive market sentiment towards the company [1] Group 1: Analyst Ratings and Expectations - Bank of America Securities has reiterated a "Buy" rating for MicroPort Medical, citing attractive risk-reward dynamics [1] - The company possesses a diversified portfolio of high-value consumable products, with the surgical robotics segment expected to be a key growth driver in the future [1] - It is projected that by 2034, surgical robotics will contribute 19% to the total revenue of MicroPort Medical [1] Group 2: Financial and Operational Support - The company's shareholder, Shanghai Shiyuan Group, is anticipated to provide financial and operational support, which may enhance the governance structure of MicroPort Medical [1] - The company is actively addressing liquidity concerns and aims to achieve profitability by the first half of 2026 through cost control measures and divesting non-core assets [1]